Abstract
This paper describes the molecular design, synthesis, and in vitro anticancer testing results of two novel pharmacophore analogues of opnurasib were obtained, for which molecular docking results predicted high inhibitory activity against the GTPase KRAS G12C. A synthetic approach previously developed in our group was used, which allows for the efficient production of target compounds in two stages from commercially available precursors. In vitro anticancer testing results showed that the obtained compounds exhibit moderate cytotoxic activity (IC50 16–23 µM) against the NCI-H358 cell line with the target KRAS G12C mutation, while exhibiting some selectivity against the AsPC-1 cell line with the non-target KRAS G12D mutation (IC50 >50 µM).
Keywords
a-(benzimidazol-1-yl)pyrroles
acrylamides
KRAS inhibitors
molecular docking
pyrrole-3-carbonitriles
α-(piperazino)pyrroles